100XBIO

Executive Summary

100XBIO is a biotechnology company pioneering a Hybrid Cytometry Platform that uniquely integrates live-cell imaging with fixed-cell analysis in a single automated workflow. Founded in 2021 and headquartered in San Francisco with a lab in Greater Boston, the company targets critical applications in immunology and oncology, such as T-cell cancer antigen screening and bispecific antibody mechanism-of-action studies. Its gentle cell handling minimizes cell loss, addressing a key pain point in cell-based assays. The platform promises to streamline and enhance research for therapeutic development, offering a differentiated value proposition in the competitive cytometry and cell analysis market. While early-stage with limited public information on funding or revenue, the company's focus on high-need areas and innovative technology positions it as a potential player in accelerating drug discovery. The executive team's background and progress remain largely undisclosed, but the platform's versatility could attract partnerships with pharma and CROs. The company operates in a growing segment where precision and efficiency in single-cell analysis are increasingly demanded.

Upcoming Catalysts (preview)

• Q3 2026Commercial Launch of Hybrid Cytometry Platform60% success
• Q4 2026Strategic Partnership with Pharma or CRO50% success
• Q2 2026Series A Funding Round70% success